Three Cases of Refractory Anti-NMDA Encephalitis Responsive to Third-Line Therapies (P10-8.015)

Three patients with anti-NMDA encephalitis were refractory to first- and second-line treatments. Third-line treatments, bortezomib and tocilizumab, achieved disease control.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000210609
Citations
1
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Three Cases of Refractory Anti-NMDA Encephalitis Responsive to Third-Line Therapies (P10-8.015)

Anatevka Ribeiro, Xiao–Tang Kong
1 citations
Neurology
Autoimmune Neurological Disorders and Treatments
1.39
article

Three Cases of Refractory Anti-NMDA Encephalitis Responsive to Third-Line Therapies (P10-8.015)

Anatevka Ribeiro, Xiao–Tang Kong
article en
1 citations

Abstract

Three patients with anti-NMDA encephalitis were refractory to first- and second-line treatments. Third-line treatments, bortezomib and tocilizumab, achieved disease control.

NeurologyVol. 104(7_Supplement_1)
University of California, Irvine (US), UC Irvine Health (US)
Zero hunger
Openalex Percentile: Top 22%
Autoimmune Neurological Disorders and Treatments
1.39
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Three Cases of Refractory Anti-NMDA Encephalitis Responsive to Third-Line Therapies (P10-8.015) — Anatevka Ribeiro, Xiao–Tang Kong · Neurology (2025) | TGRS Research Map | TGRS